Pretomanid

Breastfeeding
  • TRADE NAME: PA-824 (TB Alliance)
  • INDICATIONS: Part of a combination regimen with bedaquiline and linezolid for the
    treatment of adults with pulmonary extensively drug resistant, treatment-intolerant or nonresponsive multidrug-resistant tuberculosis.
  • CLASS: Antimycobacterial (including antitubercular)
  • HALF-LIFE: 17 hours

FDA APPROVAL DATE: 08/14/2019

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Organic anion transporter-3 substrates, Strong or moderate CYP3A4 inducers


There are no studies or available data on pretomanid use in pregnant women to inform any drug-associated risks. Breastfeeding is not recommended during treatment with pretomanid or with combination therapies.

Pretomanid is indicated for use in a limited and specific population of patients.

Our database has 50 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top